The hematopoietic potential of cryopreserved and ex vivo manipulated umbilical cord blood (UCB) samples was evaluated in vitro and in vivo. Phenotypic analysis shows that approximately 19' 0 of cord blood mononuclear cells express high levels of CD34 antigen on their surface (CD34hi). but none of a panel of lineage antigens (Lin-1, suggesting that they are hematopoietic progenitor cells that have not yet committed to a specific lineage.
The hematopoietic potential of cryopreserved and ex vivo manipulated umbilical cord blood (UCB) samples was evaluated in vitro and in vivo. Phenotypic analysis shows that approximately 19' 0 of cord blood mononuclear cells express high levels of CD34 antigen on their surface (CD34hi). but none of a panel of lineage antigens (Lin-1, suggesting that they are hematopoietic progenitor cells that have not yet committed to a specific lineage.
Approximately 1% of CD34hi/Lin-cells are primitive hematopoietic progenitors that produce B lymphoid and multiple myeloid progeny for up to 7 weeks in stromal cell cultures. Twenty-one percent (k13K) of CD34hi/Lin-cells also express low levels of the Thy-l antigen and are threefold to fourfold enriched over CD34hilLin-cells in primitive hematopoietic potential as measured by long-term culture and phenotypic analysis.
One-week liquid cultures of CD34-enriched UCB progenitor cells in the presence of interleukin (IL)-3, IL-6, and stem cell factor (SCF) results in a twofold to threefold expansion of progenitors capable of reinitiating long-term stromal cell cultures. Only the CD34hi/Thy-l+/Lin-cell population was capable of maintaining progenitors with secondary transfer HE USE OF HUMAN umbilical cord blood (UCB) as a source of marrow repopulating cells for the treatment of pediatric disease has been e~tab1ished.l.~ Given the general availability, ease of procurement, and progenitor cell content, cord blood is an attractive alternative to bone marrow or growth factor mobilized peripheral blood as a source of transplantable hematopoietic tiss~e.',~-~ The results over the past 6 years of cord blood transplantation for a variety of malignant and nonmalignant diseases have been promising. 7, 8 To date, over 60 transplants have been performed on pediatric patients using unfractionated cord blood from related and unrelated donors. Most of these patients have engrafted with no severe graft-versus-host disease in transplants with up to two HLA antigen mismat~hes,~.~ and although most patients have only been followed for l to 2 years posttransplant, donor engraftment appears to be multilineage and durable. As a result, several cord blood banks and an international cord blood registry have been established in the United States and in Europe to facilitate increased use of this source of transplantable tissue. ' However, there are potential limitations to the widespread use of UCB as a source of hematopoietic progenitors for marrow replacement and gene therapy. Early estimates suggest that there may be enough hematopoietic progenitor cells in an average cord blood sample to reconstitute adult patients," but the ability to engraft an adult may require growth factor mediated ex vivo expansion. While expansion with hematopoietic growth factors has been shown to increase the number of multipotent colony forming cells in primary tissue samples,''.'* prolonged cultures often result in the exhaustion of the proliferative and lineage potential of the most primitive progenitor^.'^"' Thus, to advance the use of UCB as a source of hematopoietic tissue for transplantation, the relationship between cellular composition and engrafting potential must be established. primitive hematopoietic cell content of various human tissues has been previously Using a mouse transplant model, Ploemacher et all8 originally demonstrated that a correlation existed between hematopoietic cells that supported long-term stromal cell cultures and those with marrow repopulating ability. Equivalent culture models for human stem cells have been reported, but have not yet been shown to predict a tissue engrafting dose of stem cell^.'^-^^ Several groups have used in vivo engraftment of human cells in immunodeficient mouse bone marrow as a transplant model system, but large numbers of donor cells andor the addition of human growth factors are required to achieve stable chimeras in most case^.'^.'^ However, even in light of recent improvements in these models, a concern still remains on whether engraftment of human progenitors on xenogeneic stromal elements accurately reflects the engraftment of these cells in human marrow. Larger animal models such as sheep and nonhuman primates have been used to critically evaluate stem cell transplantation in uteroz7 and stem cell-based gene therapy ~trategies,~' but are impractical for broad comparative studies.
A small animal model system that measures clinically relevant properties of candidate therapeutics is much more likely to be useful for extensive experimental investigation. Accordingly, severe combined immunodeficient mice implanted with human hematopoietic tissue (SCID-hu mice) have been used to evaluate the tissue engrafting potential of bone marrow and growth factor mobilized peripheral blood.3"36 Hematopoiesis has been observed for up to 6 months in these grafts and large numbers of donor-derived cells can be isolated for further experimentation. Therefore, we reasoned that the combined use of long-term stromal cell cultures and SCID-hu mouse models would be the most practical method of evaluating the effects of ex vivo manipulation on the hematopoietic potential of UCB cells. Because we were particularly interested in the development of a preclinical model system for human immunodeficiency virus (HIV) gene therapy, we predominantly focused on establishing the thymopoietic potential of cord blood progenitors using the SCID-hu thymusfliver model. Results presented in this study may have important implications for the use of human UCB as a source of hematopoietic tissue for marrow replacement and gene therapy
MATERIALS AND METHODS

Antibodies.
The following mouse monoclonal antibodies (MoAbs) have been used: CD34 (Tuk-3) obtained from A. Ziegler (University of Berlin, Germany). Sulfa-rhodamine labeled Fab'2 Tuk-3 reagents were prepared at Systemix. Fluorescein isothiocyanate (FITC) or phycoerythrin (PE)-conjugated CD2 (LeuSb), CD19 (Leul2), CD14 (LeuM3), CD15 (LeuMl), CD16 (Leulla), CD33 (LeuM9), CD4 (Leu3a), CD34 (8G12), CD10 (CALLA), and irrelevant mouse IgGl (X40) and IgG2a (X39) were purchased from Becton Dickinson (Mountain View, CA). FITC or PE-conjugated MoAb to glycophorin A (D2. IO) was purchased from AMAC (Westbrook, ME) and Tricolor (TC)-conjugated -CD8 from Caltag (South San Francisco, CA). MoAb to Thy-l (GM201) was obtained from W. Rettig (Ludwig Cancer Research Institute, New York, NY) and was detected by a specific goat antimouse IgGl-PE antibody (Caltag). MoAbs to HLA molecules MA2.1 and W6/32 were derived from hybridomas obtained from ATCC (Rockville, MD) and were fluorochrome conjugated at Systemix. Irrelevant mouse IgGl (MOPC21) and irrelevant mouse IgG3 (FLOPC21) used as indirect isotype controls were obtained from Sigma (St Louis, MO).
Cell isolation. UCB was isolated from full-term deliveries after obtaining informed consent and according to institutional guidelines of the University of Arizona Health Sciences Center. Samples were shipped as unseparated whole blood or as cryopreserved low-density mononuclear cells (LDMNC) processed at the site of collection as has been described previously.' Shipped whole blood samples were diluted 1:4 in phosphate-buffered saline (PBS) and low-density (< 1.077 g/mL) mononuclear cells were isolated (Lymphoprep, Nycomed Pharma, Oslo, Norway). Cells were washed twice in staining buffer (SB) consisting of RPMI (JRH Biosciences, Lenexa, KS) plus 2% heat inactivated fetal calf serum (FCS) (Hyclone, Logan, UT) and 10 mmolL HEPES (Sigma) and frozen in Iscove's modified Dulbecco's medium (IMDM) + 40% FCS, 10% dimethyl sulfoxide (DMSO) using a step-down freezer as previously described? Aliquots of 1 X lo7 cells were thawed before the use of each tissue for HLA typing, CD34 content, and viability determinations. Immunomagnetic bead selections were performed as previously dePhenotypic analysis and sorting of cord bloodprogenitors. Cord blood samples were preenriched for LDMNC and then stained with sulfa-rhodamine-conjugated CD34, a panel of FITC-conjugated antibodies specific for mature cells of the T lymphoid (CD2), B lymphoid (CD19), monocytic [CD14), granulocytic (CDlS), NK (CD16) or erythroid (glycophorin A) lineages (Lin) and unconjugated anti-Thy-l antibody followed by a PE-conjugated, isotypespecific secondary reagent. A portion of each sample was incubated with the appropriate isotype control antibodies to establish the background level of nonspecific staining. Cells expressing high and low levels of CD34 antigen on their surface, but no detectable antigens for mature cells (ie, CD34hilLin-and CD341o/Lin-, respectively) were isolated by flow cytometric cell sorting as previously described.34 CD34hiLin-cells were further fractionated on the basis of the expression of Thy-l by sorting all cells staining above and helow the isotype-matched control.
In vitro culture. Cord blood progenitor cells were cultured on a preestablished monolayer of a mouse stromal cell line (Sys-l) to establish lineage potential and progenitor cell frequency as previously Briefly, Sys-l stromal cells were plated in tissue culture treated plates 1 week before the experiment in WhitIocWitte medium consisting of SO% IMDM (JRH Biosciences), SO% RPMI 1640 with 10% FCS, 4 X IO-' mol& 2-mercaptoethanol, 10 mmolL HEPES, penicillin (100 U/mL) and streptomycin (100 mg/mL), and 4 mmoVL glutamine (JRH Biosciences) and allowed to grow to confluence. Bulk cultures were initiated with S,000 CD34hiLin-cells in medium supplemented with human hematopoietic cytokines (20 ng/mL leukemia-inhibitory factor [LIF], 20 ng/ mL interleukin [ILI-6 obtained from Sandoz, Basel, Switzerland) and fed weekly by demidepletion. For limit dilution analysis, 12 wells of each cell concentration were plated per population at 8 cell concentrations ranging from 1,000 cells per well to 33 cells per well in 200 pL final volume in a 96-well plate. Plates were visually scored from 2 through 7 weeks for the presence of confluent wells or those wells seeded with few cells, but demonstrating high proliferative potential. At the end of the culture period, individual wells were analyzed for lineage content by fluorescence-activated cell sorter (FACS). Linear regression analysis was used to estimate the frequencies of cells that give rise to multilineage, growth positive wells among various starting populations.
Ex vivo expansion of UCB cells was performed by culturing IO5 CD34hiLin-cells/mL for S to 9 days in WhitlocWitte media on Sys-l as described above or without stroma but supplemented with 20 ng/mL IL-3. 20 ng/mL IL-6, and S0 ng/mL stem cell factor (SCF). At the end of the culture period, cells were harvested and stained with antibodies to CD34 and the panel of lineage antigens described above and analyzed by FACS. Cells from these expansion cultures were used to engraft human organs transplanted into SCID mice or for secondary transfer analysis on Sys-l as indicated.
In vivo reconstitution of SCID-hu Thy/Liv grafts. SCID-hu thymudliver (ThyLiv) and bone model mice were constructed as previously described3'.'" and in accordance with the guidelines set forth by the Systemix Animal Care and Use Committee. For ThylLiv mice, individual pieces [ l to 2 mm) of human fetal thymus and autologous liver were placed under the kidney capsule of CB-17 scidscid mice and allowed to engraft for 3 to S months before progenitor cell reconstitution. Over this period, grafts grew to approximately 10 to IS mm and contain 10 to 100 million cells derived largely from fetal liver stem cells." For bone model mice, pieces of fetal bones were placed subcutaneously under the left and right mammary fat pad of female mice and allowed to vascularize for 8 to 12 weeks. The percentage of animals bearing viable grafts and HLA typing was determined on representative grafts from each animal cohort before experimental manipulation. Animals were preconditioned by total body irradiation with 240 rads 4 hours before surgery from a '17Cs source (Gamma cell 40, J.L. Shepherd and Assoc.
(San Fernando, CA). At the time of surgery animals were weighed and anesthetized with a mixture of ketamine HCL (SO mgkg) and xylazine HCL (25 mgkg) administered intraperitoneally. The ability of HLA-mismatched cord blood cells to reconstitute thymi was tested by direct inoculation of irradiated grafts with various cell preparations. Donor cells were resuspended at 1 to 2 X 10' cells/mL in For personal use only. on April 20, 2017. by guest www.bloodjournal.org From 
RESULTS
Isolation of stedprogenitor cells. The coordinated expression of CD34, Thy-l and a panel of lineage-specific antigens (Lin = CD2, CD14, CD15, CD16, CD19 and glycophorin A) was examined using multiple cord blood samples.
These markers have been used previously to distinguish primitive progenitors from more committed progenitors in fetal and adult bone marrow.32~42~43 Phenotypic analysis of over 100 samples indicates that in contrast to the 2% to 5% CD34 positive cells found in fetal and adult bone marrow LDMNC samples," only 1% (50.6%) of cord blood mononuclear cells express CD34. However, most (83%) of the CD34 positive cells express levels of CD34 antigen that are 100-fold greater than the average fluorescence intensity of the isotype control and CD34-negative population (Fig 1) . This is in contrast to our previous findings in fetal bone marrow in which only 25% of the total CD34+ population expresses CD34 at high levels34 and suggests that, on a per cell basis, cord blood CD34+ cells may contain greater hematopoietic activity. Further analysis shows that 21 % 5 13% of the CD34hiLin-cells also express low levels of Thy-l antigen. Therefore, in an average cord blood harvest of 4 X DlGlUSTO ET AL lo8 mononuclear cells: there are approximately 3.6 X 10' CD34hiLin-cells and 7 X IO5 CD34hi/Thy+/Lin-cells.
To establish the cell processing attributes and hematopoietic potential of cryopreserved samples, phenotypically defined progenitor cell populations were isolated from individual cord blood samples using anti-CD34 MoAbs followed by immunomagnetic bead selection and flow cytometric cell sorting. Magnetic bead selection by "microbeads" (MACS) or enzymatic release methods (glycoprotease) resulted in average CD34hinin-cell purities of 39% and 43%, respectively with moderate yields (30% to 44%) when compared with flow cytometric cell isolation that produced populations of high purities (Average [Avg] = 88%) and comparable cell yields (Avg = 40%) ( Table 1 ). The fold enrichment of progenitor cells was largely dependent on the frequency of the target population in the starting material, but was greater for sorted samples. For most tissues 3 to 5 X lo5 CD34hi/ Lin-cells could be isolated from 1 X 10' LDMNC by each of these methods, although the total processing time for magnetic bead selection (2 hours) was significantly less than that for cell sorting (8 hours). These results are similar to those reported by others using comparable methods to evaluate adult bone marrow p r o c e~s i n g .~~ For in vitro analysis, CD34 cells were enriched by bead selection and subpopulations were sorted to >90% purity.
In vitro analysis of cord blood progenitor cells. Longterm "Dexter" type cultures on a mouse stromal cell line (Sys-l) were used to evaluate the in vitro hematopoietic potential of cord blood progenitor cell The use of mouse stromal cells to evaluate human and mouse hematopoiesis has been reported by other^^',^* and has eliminated a factor of variability that is often observed with primary stromal cell isolates. CD34-selected and sort-purified cord blood progenitor cells were cultured on Sys-l in media supplemented with a minimal panel of cytokines (LIF and IL-6) previously found to be effective in stimulating multilineage cell growth in both adult and fetal bone marrow samples.44 Five to ten thousand CD34hinin-were used to initiate bulk cultures to evaluate the lineage potential of cord blood progenitors. Phenotypic analysis of 3 to 5-week cultures showed that cryopreserved cord blood progenitor cells have B lymphoid and multiple myeloid potential ( Table  2) . Mature granulocytes and monocytes were present as early as 3 weeks of culture as determined by the expression of CD15 and CD14, respectively, with very low levels of CD33 For (Fig 2) . Cells of the B lymphoid lineage expressing low levels of CD10 and CD19 were also detected as early as 3 weeks of culture, but persisted through 6 weeks and often were the predominant population of cells found late in the culture. The maintenance of CD34hi/Lin-cells was also evident in these cultures and was greater in the CD34hil Thy+ fraction than the CD34himy-fraction ( Table 2) . This finding is in agreement with previous reports that the CD34hi/Thy+ cells contain the most primitive hematopoietic activity measurable in vitro.*'.".'* Secondary transfer of cultures initiated with CD34himhy-l +kin-, but not CD34hiRhy-l -/Lin-cells, resulted in the continuous production of B lymphoid and multiple myeloid cells for up to 5 more weeks of stromal cell culture. The secondary transfer potential of primary cultures was attributable to the CD34hi/ Lin-found at the end of the primary culture (see below) and thus wells that produced these cells were presumed to 1265 be initiated by long-term culture initiating cells (LTCIC) as has been described by Sutherland et al. '6 To further evaluate the relationship between phenotype and hematopoietic potential, progenitor cell frequencies among the various CD34 subsets were determined. CD34-enriched samples were sorted into CD34hi/Lin-, CD3410/ Lin-, CD34-/Lin-, CDWhi/Thy+/Lin-or CD34hi/Thy-/ Lin-populations and plated in limiting dilution on Sys-l stromal layers. Twelve wells of each of eight cell concentrations were evaluated weekly for growth, but no consistent correlation between the contents of a well and the formation of specific culture phenotypes (ie, cobblestone areas) was observed. Therefore, all wells that grew to confluence or, when seeding very few cells, those with significant proliferative capacity (>lox the input cell number) were scored as growth positive. Wells containing only the input cell number or wells with minimal (< IO-fold) proliferative potential were not scored positive. At the end of the culture, phenotypic analysis of growth positive wells was used to establish lineage content. Final frequency calculations were based on positive wells containing at least two distinct lineages of cells as determined by phenotypic analysis. In this manner, the relative proliferative and lineage potential of the various cell populations was established. As shown in Fig 3, CD34hi/ Lin-cells from UCB contain virtually all of the cells that grow in long-term stromal cultures, while those cells expressing low levels of surface CD34 (CD341o/Lin-) or no detectable CD34 (CD34-/Lin-) had no significant growth potential. Among the cells found in highly proliferative wells were B lymphocytes, myeloid cells, and CD34+ cells. The fraction of CD34hiLin-cells giving rise to growth positive wells in a limiting dilution analysis ( = I %) did not vary significantly between 3 and 7 weeks of culture. In two tissues, CD34hiLin-cells were fractionated based on the expression of Thy-l. Both the CD34hi/Thy+/Lin-and CD34hiRhy-Lin-cells grew early in long-term stromal cell cultures, but a greater proportion of CD34himhy-1 +/ Lin-cells maintained growth positive wells cells late in the 
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culture compared with the CD34hiRhy-l -/Lin-population Growth factor stimulation of cord blood progenitor cells.
The effect of short-term stromal and liquid culture with hematopoietic cytokines on the hematopoietic potential of cord blood stem and progenitor cells was also tested. CD34-enriched samples from seven different donors were placed in liquid culture or on Sys-l monolayers supplemented with 20 ng/mL L-3, 20 ng/mL L-6, and 50 ng/mL SCF for 5 to 7 days. Cells were counted and analyzed by FACS for progenitor cell content before and after each culture. We were unable to accurately estimate the expansion of cells in stromal cell cultures because some progenitor cells would inevitably adhere to the stroma and some stroma would inadvertently be included in cell counts. However, for liquid cultures, a twofold to threefold expansion of CD34hiLin-cells was observed for most tissues tested under these conditions (Table  3) . CD34hinin-cells were reisolated from both liquid and stromal cell cultures by fluorescence activated cell sorting and analyzed for progenitor cell content in limiting dilution assays on Sys-l stromal cells. The frequency of growth positive wells among reisolated CD34hZin-cells was similar to that of primary cultures (Table 4) . Phenotypic analysis showed the presence of B lymphoid and myeloid cells in (4% v <l%). most wells, but there was little to no maintenance of CD34' cells after secondary culture (data not shown). Reanalysis for Thy-l expression in these cultures was inconclusive.
Thymic repopulating potential of UCB. To establish the thymic engrafting potential of UCB progenitor cells, the various progenitor cell preparations were used to reconstitute human thymushver grafts implanted in SCID mice. In every experiment, the CD34hiLin-content of the donor cell population was measured before injection. SCID-hu mice were prepared and reconstituted as described in Materials and Methods. Six to eight weeks after reconstitution, grafts were harvested and single cell suspensions were prepared to analyze thymopoiesis and donor reconstitution. Results are summarized in Table 5 .
Initially we tested cryopreserved LDh4NC samples immediately after thawing to establish a baseline for donor reconstitution without further manipulation. Using lo6 low-density mononuclear cells (containing 104 CD34hiLin-cells) from four HLA-mismatched tissues, only one of 50 grafts injected showed donor reconstitution (12% donor HLA positive). However, when the equivalent number of CD34hi/ Lin-cells were injected in the form of a CD34-enriched progenitor cell population, 47% (21 of 45) of the grafts from seven different tissues showed donor reconstitution ranging CD34-enriched cord blood samples were enriched by immunomagnetic bead selection and analyzed for total cell number (Cell No.), CD34hil Lin-cell number (34hi/Lin-cells) and percent CD34hi/Lin-(% CD34hi/Lin-). Samples were cultured with 20 nglmL IL-3, 20 ng/mL IL-6. and 50 ng/mL SCF for 5 to 7 days and then reanalyzed for total cell number, CD34 content, and percent. The fold increase refers to the calculated expansion of CD34hi/Lin-cells and is relative to the number of CD34hi/Lin-cells used to initiate cultures.
For from 6% to 78% (Avg = 33% donor) and only one tissue failing to reconstitute any grafts. Between lo7 and lo* total thymocytes were isolated from >95% of grafts regardless of the population or number of cells injected. A normal pattern of T-cell maturation was observed in each graft, but most donor derived T cells were immature (CD4+/CD8+) thymocytes (Fig 4) . Reconstituted grafts were dissected and grown in thymic organ culture where they matured into CD4+/CD8-and CD4-/CD8+ cells demonstrating that they had not yet matured to the single positive stage in vivo (data not shown). No differences in reconstitution potential of CD34hinin-cells enriched by bead selection or sorting was observed.
To evaluate the maintenance of thymic engrafting potential of cord blood progenitors after liquid culture in hematopoietic cytokines, 14 tissues were prestimulated in IL-3, IL-6, and SCF for 7 days before reconstitution of ThyLiv grafts. CD34hinin-content was determined and samples were used to reconstitute grafts with at least 10, OOO CD34hiLin-cells. At 6 weeks, donor engraftment was observed in 60% of the grafts (70 of 117) ranging from 5% to 98% (Avg = 42% donor). Normal thymopoiesis was also observed, and there was no significant difference in the total number of cells isolated from the grafts. CD34hinin-cells isolated (>90% purity) by flow cytometric cell sorting from expansion culture were equally capable of reconstituting grafts, while CD341oLin-cells were not. The increased number of cells isolated from expansion cultures allowed for more extensive testing of engraftment and improved the overall success rates in these experiments, but did not significantly alter the number of cells required for engraftment. The relationship between number of cells injected and engrafting potential is shown in Fig 5. Marrow repopulating potential of UCB. Similarly, we evaluated the ability of cord blood progenitors to reconstitute human fetal bones implanted subcutaneously in SCID mice. HLA-mismatched progenitor cells from liquid expansion culture of a single tissue were injected into nine bone pieces, while one bone graft from the same host was injected with buffer only as a control. After 5 weeks, bone grafts were harvested and analyzed for the presence of donor derived cells and lineage distribution. Using only 30,000 CD34hi/ Lin-cells, donor reconstitution was evident in 75% of the grafts that were recovered (Avg = 21 % donor, n = 8) ( Table  6 ). Phenotypic analysis of the samples shows the presence of donor derived myeloid cells, but a predominance of B cells and B cell progenitors in the grafts. Most donor derived progenitor cells in these grafts express low levels of CD34 and CD10 or CD19, suggesting that they are committed to the B cell lineage (Fig 6) . This bias towards B lymphopoiesis is similar to what was seen late in the in vitro culture assay.
DISCUSSION
The use of human UCB as a source of hematopoietic stem cells for cancer and gene therapy is currently being explored in our laboratories. Because cord blood samples can only be collected at parturition, it is reasonable to assume that ex vivo manipulations will be required for most clinical applications. Progenitor cell enrichment and cytokine expansion may be required to obtain sufficient numbers of cells for engraftment in many cases. The effects of these manipulations on the hematopoietic potential of cord blood progenitors are not fully understood. In this report, several different models of hematopoiesis have been used to establish the lineage potential and progenitor cell content of cryopreserved, progenitor cell-enriched and growth factor stimulated cord blood samples. Phenotypic profile was tracked throughout these studies as an indicator of cellular composition of various populations.
A combination of proliferative and lineage potential was used to measure the relative hematopoietic capacity of phenotypically defined cell populations from UCB. All of the long-term culture activity of UCB can be found among the CD34hiLin-population. A small fraction of CD34hEin-cells proliferate for up to 7 weeks of culture, produced multiple lineages of progeny, and sustain the production of progenitors with secondary transfer potential. The latter component of this activity, the ability to sustain progenitors with secondary transfer potential, is the property of an extremely primitive hematopoietic cell and is sometimes referred to as a "stem" cell. The CD34hi/Thy+/Lin-population consistently contained the highest primitive cell content measured in these in vitro assays and thus may be useful as a surrogate marker for estimating the relative number of such functionally-defined "stem" cells in UCB samples. Using this method, we calculate that the frequency of stem cells in the low-density mononuclear cell fraction of UCB is '/ l :. Interestingly, this estimate is consistent with those made by several other groups using fresh tissue and similar assays (long-term culture colony-forming cell [LTC-CFC] or longterm culture-initiating cell [LTCIC])!9-51 Thus, there are only 20 to 50 X lo" "stem" cells in a typical collection; somewhat less than the number of stem cells that are estimated to be in an average growth factor mobilized peripheral blood or bone marrow h a r v e~t . "~.~~ Our next goal was to measure the in vivo reconstituting potential of these cells. Thus, we needed to establish a model that most closely represented clinical transplantation. Hematopoietic reconstitution of patients with nonablative therapy or lineage specific anemias usually results in host: donor chimerism, reflecting the relative ability of the donor cells to compete with residual host cells for the host hematopoietic microenvir~nment.~~ As such, competitive repopulating ability is a very stringent in vivo measure of in vivo repopulating potential and may not be accurately estimated by models in which there is no competition with the human progenitor ce11s.25*27~28~54 For these reasons, engraftment of UCB progenitor cells in the SCID-hu models was used to evaluate the competitive repopulating potential of cord blood progenitor cells. The demonstration of reproducible engraftment of both thy/liv and bone grafts and the observation of stable host:donor chimerism in both the myeloid and lymphoid lineages indicates that cryopreservation and progenitor cell selection does not eliminate this stringently defined behavior and that growth factor expansion may actually enhance it. Additionally, evidence is provided by both the bone and thymus models that CD34-enriched cord blood progenitor cells will engraft across an allogeneic barrier following radiation treatment. Previous reports cite the failure of T-cell depleted marrow to engraft across allogeneic barriers and propose that a rare population of "facilitator" cells are req~ired.5~ Our current findings suggest that these cells may not be For personal use only. on April 20, 2017. by guest www.bloodjournal.org From strictly required for engraftment. We have not, however, ruled out the possibilities that the requirement for graft promoting cells is obviated by the direct injection of cells into the graft or that the number of CD34hi/Lin-cells required to obtain reproducible engraftment may be reduced by the provision of purified graft promoting cells.
In these experiments the LDMNC population did not engraft human thymi as well as CD34 selected cells. This difference in engraftment may be the result of an immune mediated graft rejection stimulated by the large number of mature cells expressing high levels of HLA antigens or, competition among cells for a limited number of thymopoietic "niches". Irrespective reduction of mature cells from the graft by positive selection of progenitor cells followed by in vitro expansion with recombinant human cytokines did not exhaust the engrafting potential of these cells and is consistent with large scale "banking" efforts. While the in vitro culture results show that these treatment results in primitive "stem" cell differentiation followed by progenitor cell expansion, it is possible that limited ex vivo expansion of cord blood progenitors will actually enhance the level of engraftment observed in patients. Similar results have been reported in other animal model system^^^.^' and with human progenitor^^^ suggesting that it may be possible to treat patients with multiple infusions of expanded cellular products derived from "banked" cord blood samples. Further investigation in this area is warranted as the consequence of driving stem cells to differentiate is a potential limit on the durability of engraftment.
The ability to cryopreserve, select, and expand progenitors without losing the ability to produce cells of the T, B, and multiple myeloid lineages indicates that cord blood may also be an excellent source of multipotent stem and progenitor cells for gene therapy. Growth factor stimulation of hematopoietic cells with the same cytokines used in these experiments has been shown to induce cell cycle activation and enhance retroviral gene transfer into stem ~e l l s .~~*~ Preliminary results on retroviral gene marking of cord blood indicates that multipotent progenitor cells capable of long-term engraftment in vivo can be transduced under these same conditions (manuscript in preparation). The durability of gene marking and expression in multiple lineages of mature cells derived from transduced stem cells can be tested using the SCID-hu model system as described here. In the context of gene therapy for HIV or other T-cell defects, the SCIDhu ThyLiv model is uniquely suited for evaluating potential vectors and expression systems in primary human T cells derived from stem cells.6' Preclinical evaluation of one such anti-HIV construct encoding the trans-dominant Rev-M10 gene (previously shown to inhibit virus replication in T-cell lines6' is currently under investigation in our laboratories.
In summary, human UCB is a suitable source of multipotent hematopoietic stem and progenitor cells for marrow replacement and (potentially) gene therapy. Cord blood can be cryopreserved, progenitor cell enriched, and expanded in vitro with hematopoietic cytokines without losing engrafting potential. A possible limitation to the use of cord blood in larger patients is the limited number of cells that can be obtained from the single opportunity for collection. Additional investigation is necessary to establish whether ex vivo expanded cord blood progenitors will engraft patients as efficiently as the larger doses of unmanipulated progenitors obtained from primary bone marrow or growth factor mobilized peripheral blood samples.
